ondansetron has been researched along with Chronic Fatigue and Immune Dysfunction Syndrome in 2 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| The, GK | 1 |
| Bleijenberg, G | 1 |
| Buitelaar, JK | 1 |
| van der Meer, JW | 1 |
| Späth, M | 1 |
| Welzel, D | 1 |
| Färber, L | 1 |
2 trials available for ondansetron and Chronic Fatigue and Immune Dysfunction Syndrome
| Article | Year |
|---|---|
The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial.
Topics: Adult; Double-Blind Method; Fatigue Syndrome, Chronic; Female; Humans; Male; Motor Activity; Ondanse | 2010 |
Treatment of chronic fatigue syndrome with 5-HT3 receptor antagonists--preliminary results.
Topics: Adolescent; Adult; Fatigue Syndrome, Chronic; Female; Humans; Indoles; Male; Middle Aged; Ondansetro | 2000 |